Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 13/20 | 0.75 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.75 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.75 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.75 |
| ▸ | PNMT | P11086 | 1/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.71 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055182 | 1.00 | DOT1L (0.75) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL5267666 | 0.94 | PRMT7 (0.75) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL5055181 | 0.94 | PRMT7 (0.75) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL5055190 | 0.94 | PRMT7 (0.75) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL14174636 | 0.86 | DOT1L (1.00) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL27092944 | 0.86 | DOT1L (0.85) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL1398379 | 0.86 | DOT1L (1.00) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL6904158 | 0.86 | DOT1L (0.85) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL10665713 | 0.86 | DOT1L (1.00) | DOT1LPRMT5DNMT3BPRMT7PNMT | |
| SCHEMBL14158851 | 0.86 | DOT1L (1.00) | DOT1LPRMT5DNMT3BPRMT7PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| EP-1844062-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | Methylgene, Inc. (CA) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006078752-A2 | INHIBITORS OF DNA METHYLTRANSFERASE | METHYLGENE, INC. (CA) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | DOT1L 24/4885PRMT5 26/4885DNMT3B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.